Have a feature idea you'd love to see implemented? Let us know!
Back to SRPT overview

SRPT Sarepta Therapeutics PE ratio, current and historical analysis

As of Jan 21, 2025, the Sarepta Therapeutics stock's PE ratio is 74.87. This results from the current EPS of $1.56 and stock price of $116.79.

SRPT PE ratio history

How has SRPT's PE ratio performed in the past
Average
N/A
Median
N/A
Minimum
N/A
Maximum
N/A

Sarepta Therapeutics PE ratio by year

Year PE ratio Change
2023 N/A N/A
2022 N/A N/A
2021 N/A N/A
2020 N/A N/A
2019 N/A N/A
2018 N/A N/A
2017 N/A N/A
2016 N/A N/A
2015 N/A N/A
2014 N/A N/A

SRPT average PE ratio chart

What is the average PE ratio of SRPT for the past years
3-year avg
N/A
5-year avg
N/A
10-year avg
N/A
15-year avg
N/A

SRPT PE vs peers

What is SRPT's PE ratio compared to its peers

Compared to its peer stock GILD, SRPT's PE ratio stands lower.

Stock name PE ratio Market cap
SRPT Sarepta Therapeutics Inc 74.42 $11.09B
GILD Gilead Sciences Inc 930.2 $115.93B
NVAX Novavax Inc N/A $1.41B
PTCT Ptc Therapeutics Inc N/A $3.48B
BCRX Biocryst Pharmaceuticals Inc N/A $1.58B
ALNY Alnylam Pharmaceuticals Inc N/A $34.38B
RNA Avidity Biosciences Inc N/A $3.59B
INSM INSMED Inc N/A $14.03B

Frequently asked questions

What is Sarepta Therapeutics's PE ratio?

The price to earnings ratio for SRPT stock is 74.87 as of Jan 21, 2025.

Why is Sarepta Therapeutics's PE ratio so high?

A company with a higher PE ratio may indicate that the market has higher growth expectations for the company's future earnings or profitability.

How is SRPT's PE ratio calculated (Sarepta Therapeutics PE ratio formula)?

You can calculate the PE ratio by dividing the most recent stock price by the trailing twelve months EPS. As of today (Jan 21, 2025), Sarepta Therapeutics's stock price is $116.79. The earnings per share for the trailing twelve months (TTM) ending Sep 2024 is $1.56. Therefore, Sarepta Therapeutics's P/E ratio for today is 74.87. PE RATIO(74.87) = STOCK PRICE($116.79) / TTM EPS($1.56)

All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.